{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-008125","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2021-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.992247+00:00","generated_at":"2026-06-30T03:15:26.980284+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VistaGen Therapeutics appoints Maggie FitzPatrick to board, replacing retiring director Brian Underdown","bullets":["Dr. Brian J. Underdown retired from VistaGen's board and all committees, effective July 21, 2021, with no disagreement.","Maggie FitzPatrick appointed as independent director; she is a former chief corporate affairs officer at Exelon and J&J.","Mary L. Rotunno appointed Chair of Corporate Governance and Nominating Committee and member of Audit Committee.","Jerry B. Gin appointed Chair of Compensation Committee; FitzPatrick also named to Corporate Governance and Nominating Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-008125","json":"https://secwatch.observer/filing/0001654954-21-008125.json","markdown":"https://secwatch.observer/filing/0001654954-21-008125.md","text":"https://secwatch.observer/filing/0001654954-21-008125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/vtgn8k_july212021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T03:15:26.980284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"276b91a715","claim":"Brian J. Underdown retired as Director at Vistagen Therapeutics, Inc..","evidence_excerpt":"Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"56f1477453","claim":"Margaret M. FitzPatrick was appointed as Director at Vistagen Therapeutics, Inc..","evidence_excerpt":"the Board appointed Margaret M. FitzPatrick to serve on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000165495421008125/0001654954-21-008125-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}